**Supplementary Table 8. Prediction results of each cancer type using 512 CpG markers measured by bsCUP-seq in 100 clinical samples.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Cancer type** | **Number of cases** | **Correct top-rank** | **Correct 2nd rank** | **Incorrect** |
| BLCA | 5 | 5 | 0 | 0 |
| BRCA | 10 | 9 | 0 | 1 (HNSC) |
| CESC | 6 | 6 | 0 | 0 |
| CHOL | 5 | 2 | 3 (2 BLCA, 1 CRAD) | 0 |
| CRAD | 10 | 9 | 0 | 1 (LUAD) |
| ESST | 9 | 9 | 0 | 0 |
| KIPAN | 12 | 12 | 0 | 0 |
| LIHC | 10 | 10 | 0 | 0 |
| LUAD | 4 | 2 | 1 (BRCA) | 1 (MESO) |
| LUSC | 2 | 1 | 0 | 1 (CRAD) |
| MESO | 1 | 1 | 0 | 0 |
| OV | 7 | 4 (2 UCEC, 2 OV) | 1 (CESC) | 2 (1 CESC, 1 KIPAN) |
| PAAD | 7 | 5 | 1 (MESO) | 1 (ESST) |
| PRAD | 1 | 1 | 0 | 0 |
| SKCM | 1 | 1 | 0 | 0 |
| THCA | 4 | 4 | 0 | 0 |
| UCEC | 6 | 3 | 2 (1 BRCA, 1 CESC) | 1 (LUAD) |
| **Total** | 100 | 84 (84%) | 8 (8%) | 8 (8%) |

\*bracket: top-ranked tumor of each sample. Abbreviations: BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical and endocervical carcinoma; CHOL, cholangiocarcinoma; CRAD, colorectal adenocarcinoma; ESST, esophageal and gastric adenocarcinoma; HNSC, head and neck squamous cell carcinoma; KIPAN, kidney renal cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovary serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PRAD, prostate adenocarcinoma; SKCM, skin cutaneous melanoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma.